ReviewClinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?
Review in Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Protocol for a Trial to Assess the Efficacy and Applicability of Isometric Strength Training in Older Adults with Sarcopenia and Dynapenia.Healthcare (Basel, Switzerland) · 2025Article
- Musculoskeletal Ultrasound Shows Muscle Mass Changes during Post-Acute Care Hospitalization in Older Men: A Prospective Cohort Study.International journal of environmental research and public health · 2022Article
- Associations of Dynapenic Obesity and Sarcopenic Obesity with the Risk of Complications in COVID-19.International journal of molecular sciences · 2022Review
- Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM.Journal of rehabilitation medicine · 2021Article
- Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19-The Role of RAGE-RAS Crosstalk.Biomolecules · 2021Review
- Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview.Frontiers in cardiovascular medicine · 2021Review
- Sarcopenia and COVID-19: A Manifold Insight on Hypertension and the Renin Angiotensin System.American journal of physical medicine & rehabilitation · 2020Article
- Pharmacological targeting of age-related changes in skeletal muscle tissue.Pharmacological research · 2020Review
- Sarcopenia and Heart Failure.Nutrients · 2020Review
- Covid-19 and the Renin Angiotensin System: Implications for the Older Adults.The journal of nutrition, health & aging · 2020Review
- Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.International journal of molecular sciences · 2019Article
- Chronic Treatment With the ACE Inhibitor Enalapril Attenuates the Development of Frailty and Differentially Modifies Pro- and Anti-inflammatory Cytokines in Aging Male and Female C57BL/6 Mice.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019Article
- Mechanisms Underlying Metabolic Syndrome-Related Sarcopenia and Possible Therapeutic Measures.International journal of molecular sciences · 2019Review
- Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure.Journal of the American Heart Association · 2017Article
- Sarcopenia in heart failure: mechanisms and therapeutic strategies.Journal of geriatric cardiology : JGC · 2016Review
- Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions.Journal of clinical and experimental hepatologyReview
- Assessment and Rehabilitation in Sarcopenic Patients.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia represents a major health problem highly prevalent in elderly and age-related chronic diseases. Current pharmacological strategies available to prevent and reverse sarcopenia are largely unsatisfactory thus raising the need to identify novel targets for pharmacological intervention and possibly more effective and safe drugs. This review highlights the current knowledge of the potential benefits of renin-angiotensin system blockade in sarcopenia and discuss the main mechanisms underlying the effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.